AbbVie (ABBV) Change in Taxes (2019 - 2026)
AbbVie (ABBV) reported Change in Taxes of -$81.0 million for Q1 2026, down 121.43% year-over-year from $378.0 million in Q1 2025, and down 112.54% quarter-over-quarter from $646.0 million in Q4 2025.
AbbVie (ABBV) Change in Taxes (2019 - 2026) Analysis & Trends
AbbVie (ABBV) has 8 years of Change in Taxes data on file, last reported at -$81.0 million in Q1 2026.
- Change in Taxes for Q1 2026 came in at -$81.0 million, down 121.43% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.2 billion (up 61.94% YoY), and the FY2025 annual result was -$762.0 million, up 76.25% from the prior year.
- Change in Taxes declined to -$81.0 million in Q1 2026 per ABBV's latest filing, from $646.0 million in the prior quarter.
- Over five years, Change in Taxes peaked at $646.0 million in Q4 2025 and troughed at -$1.8 billion in Q2 2024.
- A 5-year average of -$235.1 million and a median of $51.0 million in 2024 frame the typical range for Change in Taxes.
- The sharpest annual moves came in 2022 and 2025: Change in Taxes soared 545.45% in 2022, then plunged 905.88% in 2025.
- A 5-year view of Change in Taxes shows it stood at $358.0 million in 2022, then advanced by 14.8% to $411.0 million in 2023, then plunged by 538.69% to -$1.8 billion in 2024, then soared by 135.83% to $646.0 million in 2025, then slumped by 112.54% to -$81.0 million in 2026.
- Business Quant data shows ABBV's Change in Taxes at -$81.0 million in Q1 2026, $646.0 million in Q4 2025, and -$411.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 411.19 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -81.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 71.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | -29.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 187.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | -683.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -81.00 Mn |
| Mar 31, 2026 | -81.00 Mn |
| Dec 31, 2025 | 646.00 Mn |
| Dec 31, 2025 | 646.00 Mn |
| Sep 30, 2025 | -411.00 Mn |
| Sep 30, 2025 | -411.00 Mn |
| Jun 30, 2025 | -1.38 Bn |
| Jun 30, 2025 | -1.38 Bn |
| Mar 31, 2025 | 378.00 Mn |
| Mar 31, 2025 | 378.00 Mn |
| Dec 31, 2024 | -1.80 Bn |
| Dec 31, 2024 | -1.80 Bn |
| Sep 30, 2024 | 51.00 Mn |
| Sep 30, 2024 | 51.00 Mn |
| Jun 30, 2024 | -1.83 Bn |
| Jun 30, 2024 | -1.83 Bn |
| Mar 31, 2024 | 378.00 Mn |
| Mar 31, 2024 | 378.00 Mn |
| Dec 31, 2023 | 411.00 Mn |
| Dec 31, 2023 | 411.00 Mn |